Jonathan M. Ducore, M.D., M.P.H. for UC Davis Health

Jonathan M. Ducore, M.D., M.P.H.

Emeritus Professor

To see if Jonathan M. Ducore is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).



Pediatric Hematology/Oncology



Locations and Contact

UC Davis Comprehensive Cancer Center

UC Davis Comprehensive Cancer Center
2279 45th Street
Sacramento, CA 95817

Get Directions

Phone: 916-734-5959

Additional Numbers

Clinic Phone


Clinic Fax


Clinic Fax


Clinic Referral Phone


Physician Referrals

800-4-UCDAVIS (800-482-3284)

Philosophy of Care

Dr. Ducore believes in treating the whole patient which includes involvement of important family members and a team-approach with nurses, social workers and  other specialists and support personnel to cover all aspects of care.

Clinical Interests

Dr. Ducore is a specialist in Cancer and Blood Disorders in Children with a special interest in diseases of blood clotting and bleeding and non-malignant (non-cancerous) disorders of the blood (anemia, low white blod cells, etc). He is involved in clinical trials of the development of new drugs and therapies (including gene therapy) in the treatment of bleeding and clotting disorders.

Research/Academic Interests

Dr. Ducore's research involves the development of nre therapies, including gene therapy to treat bleeding and clotting disorders. He also studies the epidemiology of cancer and blood diseases in children and clotting disorders in adults.


Pediatric Hematology/Oncology

Center/Program Affiliation

Graduate Group in Epidemiology
UC Davis Children's Hospital
UC Davis Comprehensive Cancer Center

Undergraduate School

B.A., Biological Sciences, Rutgers University, New Brunswick NJ 1969

Medical School

M.D., Duke University School of Medicine, Durham NC 1973

Other School

M.P.H., Epidemiology, UC Berkeley School of Public Health, Berkeley CA 2002


Pediatrics, University of Cincinnati Medical Center and Cincinnati Children's Hospital, Cincinnati OH 1973-1974


Pediatrics, University of Cincinnati Medical Center and Cincinnati Children's Hospital, Cincinnati OH 1974-1975


Molecular Oncology, Laboratory of Molecular Oncology, National Cancer Institute, National Institutes of Health, Bethesda MD 1978-1980


Pediatric Oncology, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda MD 1977-1978


Pediatric Hematology/Oncology, University of Colorado Medical Center and Denver Children's Hospital, Denver CO 1975-1977

Graduated Summa Cum Laude with Distinction in Zoology, 1969

Henry Rutgers Scholar, 1968, 1969

Elected, Phi Beta Kappa, 1968

Elected, Delta Phi Alpha, 1967

American Cancer Society Junior Faculty Clinical Fellowship Award, 1982, 1983, 1984, 1985

Pipe SW, Hermans C, Chitlur M, Carcao M, Castaman G, Davis JA, Ducore J, Dunn AL, Escobar M, Journeycake J, Khan O, Mahlangu J, Meeks SL, Mitha IH, Négrier C, Nowak-Göttl U, Recht M, Chrisentery-Singleton T, Stasyshyn O, Vilchevska KV, Martinez LV, Wang M, Windyga J, Young G, Alexander WA, Bonzo D, Macie C, Mitchell IS, Sauty E, Wilkinson TA, Shapiro AD. Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors. Haemophilia. 2022 Jul;28(4):548-556. doi:10.1111/hae.14563. Epub 2022 Apr 27. PMID:35475308.

Liesner RJ, Abraham A, Altisent C, Belletrutti MJ, Carcao M, Carvalho M, Chambost H, Chan AKC, Dubey L, Ducore J, Gattens M, Gresele P, Gruel Y, Guillet B, Jimenez-Yuste V, Kitanovski L, Klukowska A, Lohade S, Mancuso ME, Oldenburg J, Pavlova A, Pollio B, Sigaud M, Vdovin V, Vilchevska K, Wu JKM, Jansen M, Belyanskaya L, Walter O, Knaub S, Neufeld EJ. Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study. Thromb Haemost. 2021 Nov;121(11):1400-1408. doi:10.1055/s-0040-1722623. Epub 2021 Feb 13. PMID:33581698.

Escobar M, Luck J, Averianov Y, Ducore J, Fernández MFL, Giermasz A, Hart DP, Journeycake J, Kessler C, Leissinger C, Mahlangu J, Martinez LV, Miesbach W, Mitha IH, Quon D, Reding MT, Schved JF, Stasyshyn O, Vilchevska KV, Wang M, Windyga J, Alexander WA, Al-Sabbagh A, Bonzo D, Mitchell IS, Wilkinson TA, Hermans C. PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors. Haemophilia. 2021 Nov;27(6):911-920. doi:10.1111/hae.14418. Epub 2021 Oct 6. PMID:34614267.

Escobar M, Castaman G, Boix SB, Callaghan M, de Moerloose P, Ducore J, Hermans C, Journeycake J, Leissinger C, Luck J, Mahlangu J, Miesbach W, Mitha IH, Négrier C, Quon D, Recht M, Schved JF, Shapiro AD, Sidonio R Jr, Srivastava A, Stasyshyn O, Vilchevska KV, Wang M, Young G, Alexander WA, Al-Sabbagh A, Bonzo D, Macie C, Wilkinson TA, Kessler C. The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. Haemophilia. 2021 Nov;27(6):921-931. doi:10.1111/hae.14419. Epub 2021 Oct 11. PMID:34636112.

Marlow EC, Ducore J, Kwan ML, Cheng SY, Bowles EJA, Greenlee RT, Pole JD, Rahm AK, Stout NK, Weinmann S, Smith-Bindman R, Miglioretti DL. Leukemia Risk in a Cohort of 3.9 Million Children with and without Down Syndrome. J Pediatr. 2021 Jul;234:172-180.e3. doi:10.1016/j.jpeds.2021.03.001. Epub 2021 Mar 6. PMID:33684394.

Stonebraker JS, Ducore JM. Modelling future usage and cost of factor and emicizumab to treat haemophilia A for the US Western States Region IX haemophilia treatment centres. Haemophilia. 2021 Jan;27(1):e22-e29. doi:10.1111/hae.14159. Epub 2020 Oct 4. PMID:33012106.

Santagostino E, Lalezari S, Reding MT, Ducore J, Ng HJ, Poulsen LH, Michaels LA, Linardi CCG. Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial. Thromb Res. 2019 Nov;183:13-19. doi:10.1016/j.thromres.2019.08.023. Epub 2019 Aug 26. PMID:31513978.

George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones BJ, Ducore J, Cuker A, Sullivan LM, Majumdar S, Teitel J, McGuinn CE, Ragni MV, Luk AY, Hui D, Wright JF, Chen Y, Liu Y, Wachtel K, Winters A, Tiefenbacher S, Arruda VR, van der Loo JCM, Zelenaia O, Takefman D, Carr ME, Couto LB, Anguela XM, High KA. Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. N Engl J Med. 2017 Dec 7;377(23):2215-2227. doi:10.1056/NEJMoa1708538. PMID:29211678.

Buckner TW, Leavitt AD, Ragni M, Kempton CL, Eyster ME, Cuker A, Lentz SR, Ducore J, Leissinger C, Wang M, Key NS. Prospective, multicenter study of postoperative deep-vein thrombosis in patients with haemophilia undergoing major orthopaedic surgery. Thromb Haemost. 2016 Jul 4;116(1):42-9. doi:10.1160/TH15-10-0802. Epub 2016 Mar 24. PMID:27009484.

Ducore JM, Miguelino MG, Powell JS. Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B. Expert Rev Hematol. 2014 Oct;7(5):559-71. doi:10.1586/17474086.2014.951322. Epub 2014 Aug 21. PMID:25142322.